Tocilizumab (Actemra) and Tocilizumab Biosimilars coverage
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical policy governing prior authorization and medical necessity criteria for tocilizumab (Actemra) and specified biosimilars for outpatient/inpatient use for BCBS North Carolina members.
July 2026: For CRS, allowed proactive prescribing in anticipation of CAR-T therapy, adjusted maximum units to reflect four 800 mg doses, and extended approval duration to 180 days (max 4 doses).
April 2026: For SSc-ILD, separated intolerance/hypersensitivity from FDA contraindication criteria; updated continuation criteria to differentiate diagnoses and redirect to initial criteria for indications except SSc-ILD.
October 2025: Added HCPCS Q5156 for Avtozma and deleted miscellaneous J/C codes termed 9/30/2025.
July 2025: Added biosimilar Avtozma (tocilizumab-anoh) as non-preferred with requirement to trial and fail Tyenne; added dosing, max units, and HCPCS references.
June 2024: Added biosimilars Tyenne (Q5135) and Tofidence (Q5133) and updated naming of policy to include biosimilars.
Coverage and Medical Necessity Criteria
inv-01: Initial Therapy Criteria
Covered when ALL of the following are met (criteria vary by indication as detailed below):
See indication‑specific nodes below for age, required prior trials, and documentation expectations.
Medical record documentation required for prior trials, intolerance/contraindication, or clinical benefit (see policy).
Medical record documentation required.
Medical record documentation required.
Medical record documentation required.
Documentation of CAR T cell therapy and whether CRS is present or the agent is being prescribed proactively is required.
Specific active‑disease definitions and required HRCT confirmation are specified in the policy; medical record documentation required.
Medical record documentation and FDA MedWatch submission (when applicable) required.
inv-02: Continuation Therapy
Continuation therapy covered when criteria below are met:
Medical record documentation required to demonstrate prior approval or that initial criteria would have been met.
Documentation of clinical response required in the medical record.
Prescriber specialty, no combination biologics/Otezla, quantity limits, and site‑of‑care criteria continue to apply.
inv-03: Continuation Criteria / Dosing by Indication
Continuation criteria and dosing by indication per FDA label and product‑specific details
Maximum units for CRS listed as 3,200 in product tables; proactive (on‑hand) prescribing prior to CAR T cell therapy is allowed per July 2026 update.
Different biosimilars have assigned HCPCS codes (see coding).
Follow FDA label and product‑specific HCPCS guidance.
Follow FDA label dosing for pediatric indications.
Documentation of pulmonary function and clinical benefit required for continuation.
inv-03: Continuation Criteria / Dosing by Indication
Site of Care Medical Necessity Criteria
inv-04: Quantity Limit Exceptions
Quantity Limit Exception Criteria
The requested tocilizumab product must not be used in combination with another biologic immunomodulator agent or apremilast (Otezla®). This combination prohibition applies to all initial and continuation requests and medical record documentation must support the absence of concomitant biologic or Otezla use.
An inpatient admission that is solely for the purpose of administering the injection or infusion is not supported. Inpatient administration is allowable only when the medical necessity criteria are met and the admission is not for the sole purpose of drug administration; otherwise the Site of Care criteria require administration in an alternate setting (home infusion or physician office) or meeting one of the outpatient hospital exceptions.
Requests that exceed the policy's maximum units allowed for the duration of approval or that do not meet Site of Care requirements for inpatient or outpatient hospital administration may be considered not medically necessary. Quantity Limit Exception rules apply and require documentation when a dose exceeds standard limits (see exception criteria).
Requests that exceed labeled dosing without required prescriber documentation may be denied. If the requested quantity exceeds the maximum FDA‑labeled dose or the safest studied dose, the prescriber must submit supporting documentation (medical records or fax form) showing prior use, duration, and prior medication trials/failures. Additionally, requests for inpatient administration that are solely for infusion or injection may be considered not medically necessary under the Site of Care criteria.
Billing and Coding References
| J3262 | tocilizumab (Actemra) HCPCS (referenced) |
| Q5156 | tocilizumab-anoh (Avtozma) HCPCS |
| Q5156 | HCPCS for Avtozma (tocilizumab-anoh) IV/SC |
| Q5133 | HCPCS for Tofidence (tocilizumab-bavi) IV |
| Q5135 | HCPCS for Tyenne (tocilizumab-aazg) IV/SC |
| C9399 | Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025) |
| J3490 | Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025) |
| J3590 | Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025) |
Provider Requirements, Authorization, and Documentation
Prior Authorization and Coding References
Prior authorization required for tocilizumab products and biosimilars administered by a healthcare professional. See HCPCS coding and maximum units in the FDA label reference tables for each product; requests that do not meet medical necessity criteria may be denied.
Quantity Over Labeled Maximum
If the requested quantity (dose) exceeds the FDA labeled maximum or the safest studied dose per the manufacturer's product insert, the prescriber must submit supporting documentation demonstrating medical necessity for the higher dose. Documentation may include medical records or a completed fax form showing duration of use at the higher dose and prior medication trials/ failures.
- Requests exceeding FDA labeled maximum will require prescriber-submitted documentation (medical records or fax form).
- Quantity requested for titration may be authorized for up to a 90-day titration period if criteria are met.
Site-of-Care Inpatient Denial Risk
Requests for inpatient administration will be denied when the inpatient admission is solely for the purpose of administering the injection or infusion. Outpatient hospital administration is allowed only when medical necessity criteria are met and one of the listed site-of-care conditions is present (e.g., history of severe adverse event, increased risk conditions, inability to adhere to regimen, new to therapy, re-initiation, or change in formulation). Otherwise, administration should occur in a home infusion or physician office setting.
- Inpatient administration not allowed if admission is solely to receive infusion/injection.
- Outpatient hospital administration requires meeting one of the specified criteria (severe adverse event history, high-risk conditions, unsuccessful management of mild adverse events, inability to adhere, new to therapy/re-initiation, change in formulation).
- If site-of-care criteria not met, administration must occur in home-based infusion or physician office setting.
Documentation for Higher-than-Labeled Doses
When requesting doses above the labeled maximum, prescribers must submit medical record documentation supporting the dosing rationale. Acceptable evidence includes records showing the length of time the higher dose has been used, what other medications and doses were tried and failed, or completion of the policy fax form reflecting this information. Lack of supporting documentation may result in denial.
- Documentation must show dosing rationale and prior therapy history if dose > FDA labeled maximum.
- Submitted documentation may be medical records or a completed fax form reflecting clinical justification and treatment history.
Step Therapy Among Tocilizumab Products
Step therapy applies across tocilizumab products: trial and inadequate response to the preferred biosimilar Tyenne (tocilizumab-aazg) is required before approval of non-preferred tocilizumab products (e.g., Actemra, Avtozma, Tofidence), unless an approved exception applies.
- Step therapy requires trial and inadequate response to Tyenne (tocilizumab-aazg) prior to non-preferred tocilizumab agents.
- Medical record documentation of the trial and inadequate response is required.
Biosimilar Trial-and-Failure
For non-preferred tocilizumab biosimilars (e.g., Avtozma/tocilizumab-anoh, Tofidence/tocilizumab-bavi, and Actemra when considered non-preferred), approval requires trial and failure of the preferred biosimilar Tyenne (tocilizumab-aazg) OR documented intolerance, FDA-labeled contraindication, or a serious adverse event to Tyenne that is not expected with the requested agent. If relying on a serious adverse event, the prescriber must submit a completed FDA MedWatch Adverse Event Reporting Form.
- Acceptable exceptions to trial-and-failure: documented intolerance, contraindication, or serious adverse event to Tyenne (with MedWatch submission).
- Medical record documentation required for the trial failure or exception; prescriber must submit FDA MedWatch form when a serious adverse event is the basis for exception.
Clinical Background and Context
Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist with multiple FDA‑approved indications including adult rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis (systemic and polyarticular forms), CAR T cell therapy–associated cytokine release syndrome (CRS), and systemic sclerosis‑associated interstitial lung disease (SSc‑ILD). Both intravenous and subcutaneous formulations are addressed by this policy, and indication‑specific dosing, age thresholds, and administration route requirements (for example, IV only for CRS) are specified in the coverage criteria.
Definitions and Condition Summaries
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.